Figure 2 | Signal Transduction and Targeted Therapy

Figure 2

From: Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Figure 2

Clinical responses of all patients. (a) The progression-free survival (PFS) for all participating patients. More than 50% of the patients achieved a 6-month PFS. (b, c) The positron emission tomography-computed tomography (PET-CT) images of patients UPN03 and UPN07, respectively. The higher uptake in the cervical lymph node of UPN03 disappeared at the 3-month time point after the Chimeric Antigen Receptor-modified T-20 (CART-20) cell infusion. The lesions of patient UPN07 at the mediastinum and groin disappeared at the 6-month time point after the CART-20 cell infusion. (d) The time of progression-free survival after the CART-20 cell infusions was significantly longer than that observed after the last salvage chemotherapies. The light brown bars denote responses after salvage chemotherapy; the dark brown bars demonstrate the PFS after the CART-20 cell infusion.

Back to article page